Tempus AI, Inc. (TEM) Total Return CAGR:-29.95%(TTM)
Over the latest trailing 12-month period, Tempus AI, Inc. (TEM)'s total return cagr is -29.95%. The comparable SPY value is +22.75%. Year-to-date total return is -16.02%. Total return includes price appreciation and reinvested dividends.
Over the past 12 months, Tempus AI, Inc.'s Total Return CAGR is -29.95%. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of Tempus AI, Inc.'s investment performance.
TEM Total Return CAGR Chart
Tempus AI, Inc. (TEM)
TEM Quarterly Total Return (YoY)
Total Return Index growth vs the same quarter one year earlier, last 5 quarters.
TEM Total Return CAGR History
| Year | Start Total Return | End Total Return | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | 146.71 | 123.20 | -23.50 | -16.02% | -16.02% |
| 2025 | 83.88 | 146.71 | +62.83 | +74.91% | +74.91% |
Quarterly Total Return: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | 123 | +9.7% | -22.0% |
| Q1 2026 | 112 | -23.4% | -6.3% |
| Q4 2025 | 147 | -26.8% | +74.9% |
| Q3 2025 | 201 | +27.0% | +42.6% |
| Q2 2025 | 158 | +31.7% | +81.5% |
| Q1 2025 | 120 | +42.9% | — |
| Q4 2024 | 84 | -40.4% | — |
| Q3 2024 | 141 | +61.7% | — |
| Q2 2024 | 87 | — | — |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky